Relay Therapeutics

Relay Therapeutics

Biotechnology
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. the Dynamo platform integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-4008, RLY-2608, and GDC-1971 (formerly known as RLY-1971).

$3.9B

Market Cap • 10/9/2026

2015

(11 years)

Founded

2020

(6 years ago)

IPO

NASDAQ

Listing Exchange

Flag of United States

United States

Country

Valuation

P/B

4,4

P/S

378,6

P/EBITDA

—

P/OCF

—

P/FCF

—

P/E

—

BVPS

4,1

EPS

—

Market Cap

Market Cap

3,9B

EV

3B

EV/Revenue

293,5

EV/EBITDA

-9,9

EV/EBIT

-9,8

Payout

Dividend Per Share

0

Dividend Yield

0%

Buyback Yield

-11,8%

Total Yield

-11,8%

Payout

0%

Retained Earnings

-2,2B

Profitability

Gross Margin

100%

EBITDA Margin

—

EBIT Margin

—

Net Margin

—

D&A/EBITDA

0%

R&D/Revenue

2615,7%

Capex/Revenue

0%

Capex/D&A

0%

Capex/OCF

0%

SBC/OCF

—

% PPE

3,9%

% Goodwill

0%

ROE

—

ROIC

—

Growth

CAGR Revenue 5Y

-34,3%

CAGR Op. Income 5Y

5,5%

CAGR Net Income 5Y

3,9%

CAGR EPS 5Y

8,4%

CAGR OCF 5Y

39,1%

Leverage

N.D./EBITDA

2,9

Debt/Equity

0%

Current Ratio

18,3

Quick Ratio

17,9

Interest Coverage

—

Premium

Unlock 100% of the data and have immediate access on more than 6.000 companies with updated information!
  • Unrestricted access
  • Unlimited data history
  • Analysis videos
  • Quarterly highlights
  • Customizable financials table
  • Ranking
  • Discussions

...and much more!

Get Premium